Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 23, 2019. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single transaction involving American Depositary Shares (ADSs).
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $38.70 per ADS
- Transaction Volume: 8,994 ADSs
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine vesting event under the GlaxoSmithKline Share Value Plan.
Management Commentary and Transaction Details
The filing discloses a transaction by Mr. B McNamara, CEO of GSK Consumer Healthcare. On January 22, 2019, an award of 8,994 ADSs vested. Of this amount, 4,430 ADSs were automatically withheld to satisfy tax liabilities. The transaction was executed on the New York Stock Exchange (XNYS).
Investor Verification Checklist
- Verify the identity of the Principal Director or Manager (PDMR) involved: Mr. B McNamara.
- Confirm the vesting date of January 22, 2019, and the execution date of January 23, 2019.
- Note that 49.2% of the vested shares (4,430 of 8,994) were withheld for taxes, reducing the net share count received.
- Understand that this filing contains no data on GSK's overall financial performance for the period.